AbbVie scores surprisingly good Q2 results but pipeline worries persist

Fierce Pharma ------- July has been a tough month for AbbVie, marked by a stinging patent loss on its megablockbuster Humira and a negative verdict in the first bellwether case against its once-blockbuster testosterone drug AndroGel. Even the better-than-expected earnings announced today created some concerns among investors.That's because the Illinois pharma can’t escape the burden presented by rheumatoid arthritis treatment Humira, which accounts for 60% of its sales and is the world’s top-selling drug. Sales of the drug rose 14% year-over-year during the quarter to $4.7 billion, beating analysts’ expectations, but the company itself has predicted that biosimilar competition will start taking a toll on sales next year. That has left investors desperate for signs of anything coming out of the company’s pipeline that will help make up for the impending loss. To learn more click on the picture below to read the article.